To prove that the c-MYC-mRNA drug inhibited c-MYC in vivo in a titratable dose-dependent manner in lethal pancreatic cancer, we titrated the dose of the MYC-mRNA drug from the first in vivo experiment of 3× IC50 (3.6 μg) to 6× IC50 (21.6 μg) and 9× IC50 (32 μg). Here, MYC is linked to pancreatic neoplasm.